Brightening the Optical Flow through Posit Arithmetic

As new technologies are invented, their commercial viability needs to be carefully examined along with their technical merits and demerits. The posit data format, proposed as a drop-in replacement for IEEE 754 float format, is one such invention that requires extensive theoretical and experimental study to identify products that can benefit from the advantages of posits for specific market segments. In this paper, we present an extensive empirical study of posit-based arithmetic vis-\`a-vis IEEE 754 compliant arithmetic for the optical flow estimation method called Lucas-Kanade (LuKa). First, we use SoftPosit and SoftFloat format emulators to perform an empirical error analysis of the LuKa method. Our study shows that the average error in LuKa with SoftPosit is an order of magnitude lower than LuKa with SoftFloat. We then present the integration of the hardware implementation of a posit adder and multiplier in a RISC-V open-source platform. We make several recommendations, along with the analysis of LuKa in the RISC-V context, for future generation platforms incorporating posit arithmetic units.Comment: To appear in ISQED 202

ВЛИЯНИЕ ТРАНСПОРТНыХ ЗАДЕРЖЕК ШЛАМОВыХ ПОТОКОВ НА ПРОДОЛЖИТЕЛЬНОСТЬ НЕСТАЦИОНАРНОГО РЕЖИМА РАБОТы ВОДНО-ШЛАМОВыХ СИСТЕМ

Проблема и ее связь с научными и практическими задачами. Все подре-шетные воды гравитационного отделения аккумулируются в зумпфах большой емкости и далее перекачиваются на операцию предварительной регенерации в гидроциклоны, классификаторы или сгустители. При этом необходимо обеспе-чить подачу на самую верхнюю отметку для дальнейшего распределения шла-мовых потоков самотеком. Как правило, такие потоки характеризуются высо-кими транспортными задержками. Магистрали для шламовых потоков перед узлами вывода имеют меньшие геометрические размеры, переносят незначи-тельное количество пульпы по сравнению с вводными коммуникациями

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049